GEn1E Lifesciences Publishes Breakthrough Research Unveiling Novel Mechanism of Action of Dual Signal Modulators for Anti-inflammatory and Endothelial-Stabilizing Therapies GEn1E Lifesciences today announced the publication of a landmark study in the prestigious Journal of Pharmacology and Experimental Therapeutics (JPET)

GEn1E Lifesciences Adds to Development Pipeline with Exclusive Option to License University of Maryland, Baltimore’s MUC1-Ecto-Domain Anti-Bacterial Agent Provides GEn1E the potential to enter clinic with a therapy for Pseudomonas infections in Cystic Fibrosis patients PALO ALTO, Calif., Nov. 19, 2018 (GLOBE NEWSWIRE) -- GEn1E Lifesciences Inc....

GEn1E Lifesciences Granted Exclusive Option to License University of Maryland, Baltimore’s Selective P38 Kinase Inhibitor Access to University of Maryland, Baltimore’s broadly applicable P38 Kinase inhibitor technology offers GEn1E the potential to enter the clinic with an acute lung injury/acute respiratory distress...